Literature DB >> 9093834

Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines.

E M Rouppe van der Voort1, B Kuipers, H F Brugghe, L M van Unen, H A Timmermans, P Hoogerhout, J T Poolman.   

Abstract

Synthetic peptides derived from the predicted loops 1 and 4 of meningococcal PorA, sero-subtype P1.7,16, were used to study the epitope specificity of murine and human PorA P1.7,16 bactericidal antibodies. The predicted loops 1 and 4 are surface exposed and carry in their apices the sero-subtype epitopes P1.7 (loop 1) or P1.16 (loop 4), respectively. Peptides were synthesized as mono- and multimeric peptides. Murine monoclonal and polyclonal antibodies were induced with meningococcal whole cell preparations. Polyclonal antibodies were evoked in volunteers after one immunization with 50 micrograms or 100 micrograms protein of a hexavalent meningococcal PorA vesicle vaccine. The induction of PorA antibodies was determined in ELISA using purified PorA P1.7,16. The epitope specificity of anti-PorA antibodies for both murine and human antibodies could be demonstrated by direct peptide ELISA using overlapping multimeric peptides almost spanning the entire loops 1 or 4 of the protein. The capacity of peptides to inhibit the bactericidal activity of murine and human antibodies was investigated using meningococcal strain H44/76 (B:15:P1.7,16) as a target strain. Bactericidal activities could be inhibited with both monomeric and multimeric peptides derived from epitopes P1.7 and P1.16.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9093834     DOI: 10.1111/j.1574-695X.1997.tb01006.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  8 in total

1.  Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity.

Authors:  Wendell D Zollinger; Elizabeth E Moran; Deborah H Schmiel
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

2.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

3.  Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development.

Authors:  C T Sacchi; A P Lemos; T Popovic; J C De Morais; A M Whitney; C E Melles; L M Brondi; L M Monteiro; M V Paiva; C A Solari; L W Mayer
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

4.  Differences in surface expression of NspA among Neisseria meningitidis group B strains.

Authors:  G R Moe; S Tan; D M Granoff
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

5.  Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis.

Authors:  J Wang; G A Jarvis; M Achtman; E Rosenqvist; T E Michaelsen; A Aase; J M Griffiss
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

6.  Stability of PorA during a meningococcal disease epidemic.

Authors:  A F Devoy; K H Dyet; D R Martin
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

7.  In silico studies of outer membrane of Neisseria meningitidis por a: its expression and immunogenic properties.

Authors:  Ava Behrouzi; Saeid Bouzari; Seyed Davar Siadat; Shiva Irani
Journal:  Int J Mol Cell Med       Date:  2014

8.  The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.

Authors:  Peter T Beernink; Jutamas Shaughnessy; Rolando Pajon; Emily M Braga; Sanjay Ram; Dan M Granoff
Journal:  PLoS Pathog       Date:  2012-05-10       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.